BDMD
Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.
Baird Medical Investment Holdings Limited (BDMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Momentum (F). The rating has held at C+ for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | B (3.2) | A- (4.0) | F (0.6) | C+ (2.6) | C+ (2.8) |
| 2026-11-10 | B (3.4) | B (3.2) | A- (4.0) | D- (0.9) | C+ (2.6) | C+ (2.8) |
| 2026-11-03 | B (3.4) | B (3.2) | A- (4.0) | D- (0.7) | C+ (2.7) | C+ (2.8) |
| 2026-10-27 | B (3.4) | B- (3.1) | A- (4.0) | D- (0.9) | C+ (2.6) | C+ (2.8) |
| 2026-10-20 | B (3.4) | B- (3.1) | A- (4.0) | D- (1.1) | C+ (2.6) | C+ (2.8) |